Anticipated $0.64 EPS for Teva Pharmaceutical Industries Limited (TEVA) on May, 10

April 17, 2018 - By Sheila Anderson

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Corporate Logo

Investors wait Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s quarterly earnings on May, 10., according to RTT. The EPS diference is $0.39 or 37.86 % down from last years number. Previous year: $1.03; Analysts forcast: $0.64. If EPS of $0.64 is revealed the profit of TEVA could reach $650.81M giving it 7.05 P/E. -29.67 % negative EPS growth is what Wall Street’s forecasts after $0.91 reported EPS last quarter. TEVA reached $18.06 on during the last trading session after $0.01 change.Currently Teva Pharmaceutical Industries Limited is downtrending after 49.50% change in last April 17, 2017. TEVA has 5.20 million shares volume. The stock underperformed the S&P 500 by 61.05%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Total analysts of 26 have positions in Teva Pharmaceutical Industries Limited American Depositary Shares (NYSE:TEVA) as follows: 6 rated it a “Buy”, 7 with “Sell” and 13 with “Hold”. The positive are 23%. Since October 20, 2017 according to StockzIntelligence Inc Teva Pharmaceutical Industries Limited American Depositary Shares has 52 analyst reports. On Monday, November 13 the rating was downgraded by JP Morgan to “Underweight”. On Friday, February 9 the rating was downgraded by Gabelli to “Hold”. The stock rating was maintained by Cowen & Co with “Hold” on Thursday, February 8. In Monday, November 13 report J.P. Morgan downgraded the stock to “Sell” rating. In Wednesday, November 29 report RBC Capital Markets maintained the stock with “Sell” rating. On Friday, December 22 the firm has “Hold” rating given by Cantor Fitzgerald. On Tuesday, March 13 the stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given by Guggenheim. On Tuesday, January 16 the company was maintained by Guggenheim. The company rating was maintained by Leerink Swann on Friday, February 9. On Tuesday, November 7 the stock has “Reduce” rating by HSBC.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.The firm is valued at $18.37 billion. It operates through two divisions, Generic Medicines and Specialty Medicines.Currently it has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.